Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brigatinib Approval Validates Ariad Buy, But Can Takeda Carve A Position?

Executive Summary

The US approval of the targeted kinase inhibitor brigatinib seems to provide early validation of Takeda's recent acquisition of Ariad, but can the molecule carve its own niche amid intensifying same-class competition?

Advertisement

Related Content

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Biopharma Quarterly Deal-Making Statistics, Q1 2017
Rydapt And Alunbrig Approvals Headline Good Week For Targeted Oncologics At US FDA

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098652

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel